CLPTM1L and non-small cell lung carcinoma: CLPTM1L was increased by an average of 2.24 fold reaching an overall significance for differential expression in 30 Stage I NSCLC patients (p  = .0028, Two-tailed Student’s T-Test) (Figure 1A).